Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)
Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com
CIN. : L74899DL1978PLC009181

A CSR Initiative

September 23, 2026

The Department of Corporate Services- Listing **BSE Ltd,** Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 **Scrip Code: 507789**	The Department of Corporate Services- Listing **National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 **Symbol: JAGSNPHARM**

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited, strengthening Jagsonpal's presence in Women's Health

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Para A(1) of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulations"), we wish to inform you that Jagsonpal Pharmaceuticals Limited ("Company") has entered into a Business Transfer Agreement ("BTA") with Group Pharmaceuticals Limited ("Seller") on September 23, 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA.

The acquisition of the portfolio is in line with the Company's strategic objective of strengthening and expanding its pharmaceutical portfolio, enhancing its presence in the relevant therapeutic segments and expanding its market reach.

The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 updated as on January 30, 2026 are enclosed herewith as **Annexure-A**.

A press release being issued by the Company in this regard is attached as **Annexure -B.**

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

PRATHAM RAWAL
Digitally signed by PRATHAM RAWAL
Date: 2026.09.23 17:45:46 +05'30'

Pratham Rawal

Company Secretary & Compliance office

Annexure-A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No.	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Not applicable. Company proposes to acquire the Wellness Portfolio of Group Pharmaceuticals Limited. Turnover of the portfolio for FY 2025-26 was ₹24.6 Crores.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The said business transfer does not fall within the purview of related party transactions. None of the promoter/promoter group/group companies have any interest in the Wellness Portfolio / Seller.
c)	Industry to which the entity being acquired belongs	Pharmaceutical Industry
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition will strengthen the Company's pharmaceutical portfolio, expand its presence across relevant therapeutic segments and enhance market reach.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	None
f)	Indicative time period for completion of the acquisition	On or before **01 November, 2026**, subject to fulfilment of conditions precedent and other terms of the BTA.
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of upto ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores.
h)	Cost of acquisition or the price at which the shares are acquired	Not applicable
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	Not applicable
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable. The Company proposes to acquire the Wellness Portfolio of Group Pharmaceuticals Limited, which is engaged in the pharmaceutical business, on a going-concern basis by way of slump sale. The business has presence in India and comprises the identified products, assets, contracts, employees and other arrangements relating to the business.

Jagsonpal Pharmaceuticals to acquire Wellness Portfolio of Group Pharmaceuticals.

Acquisition to strengthen product portfolio and existing market presence

Gurugram, India | September 23, 2026 – Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced the execution of a Business Transfer Agreement (“BTA”) with Group Pharmaceuticals Limited (“Group Pharma”) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves Initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of upto ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of the conditions precedent and other terms and conditions stipulated under the BTA.

This business brings in an established portfolio of products and an existing market presence, which we intend to integrate with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies.

Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: " *The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.”*

Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: *“We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.”*

The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA.

Think law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over five decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, and Dermatology segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com, Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750